+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Injections for SMA Market - Global Forecast 2026-2032- Product Image
Injections for SMA Market - Global Forecast 2026-2032- Product Image
Sale

Injections for SMA Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118347
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Injections for SMA Market is projected to reach USD 5.10 Billion in 2026. It is expected to continue growing at a CAGR of 13.67%, reaching USD 11.24 Billion by 2032.

Introduction to Injections for Spinal Muscular Atrophy

Injections for spinal muscular atrophy (SMA) are part of a broader shift toward disease-modifying care for a rare, inherited neuromuscular disorder. Clinical value depends on timely diagnosis, genetic confirmation, treatment eligibility, administration capability, monitoring, and sustained access. Care pathways increasingly connect newborn screening, specialist assessment, rehabilitation, respiratory support, nutrition, and long-term follow-up rather than treating injections as an isolated intervention.

Transformative Shifts Reshaping SMA Injection Care

SMA management is being reshaped by earlier diagnosis, broader newborn-screening activity, improvements in genetic testing, and treatment decisions based on age, disease stage, and functional status. Health systems are also developing more coordinated pathways that bring together neurologists, geneticists, pharmacists, infusion teams, respiratory specialists, and rehabilitation providers. Access remains influenced by reimbursement rules, referral capacity, treatment-center distribution, administration requirements, and the ability of families to maintain regular monitoring.

How Artificial Intelligence Is Influencing SMA Injection Pathways

Artificial intelligence can support SMA care by helping identify patients who may warrant confirmatory testing, organizing longitudinal clinical records, and improving interpretation of functional, respiratory, and imaging data. It may also assist trial recruitment, safety surveillance, and operational scheduling. These applications require representative datasets, clinical validation, explainability, privacy safeguards, and human oversight. AI should complement-not replace-genetic confirmation, specialist judgment, informed consent, or direct assessment of patient function.

Regional Insights: Access and Delivery Across Six Geographies

North America generally combines advanced specialist infrastructure with established rare-disease networks, although affordability, prior authorization, and geographic access can shape treatment continuity. Europe benefits from coordinated clinical expertise and cross-border research, while national reimbursement and health-technology assessment processes create variation. Asia-Pacific includes sophisticated centers alongside substantial differences in screening, specialist availability, and rural access. Latin America continues to expand rare-disease diagnosis and referral capacity, with funding and distribution challenges remaining important. The Middle East is strengthening specialized services and genomic capabilities, while access can differ sharply between well-resourced urban systems and other settings. Africa faces constraints in screening, genetic testing, specialist coverage, and treatment logistics, making partnerships, workforce development, and sustainable referral models especially important.

Group Insights: Policy and Collaboration Contexts

ASEAN markets are characterized by varied healthcare financing, uneven newborn-screening implementation, and differing specialist capacity, creating a strong need for regional knowledge exchange and referral coordination. BRICS members combine significant scientific and clinical capabilities with wide variation in affordability, public procurement, and geographic coverage. The European Union supports research collaboration and shared clinical knowledge, but national assessment and reimbursement decisions remain central. G7 systems generally have mature specialist services and evidence infrastructure, while still addressing affordability and equitable access. GCC countries are investing in advanced healthcare and genomics, with continued emphasis on workforce and referral integration. NATO members span diverse health systems, but collaboration in research, preparedness, and specialized care can support continuity for mobile populations.

Country Insights Across Fifteen Priority Markets

Australia combines strong specialist medicine with geographic dispersion that can complicate access outside major centers. Brazil and Mexico continue to face regional inequalities in diagnosis, reimbursement, and specialist referral. Canada’s publicly organized care is balanced by distance and provincial variation. China is expanding genomic and specialist capacity across a large and diverse health system. France, Germany, Italy, Spain, and the United Kingdom have established rare-disease expertise, while approval, assessment, commissioning, and regional delivery arrangements differ by country. India has substantial clinical and research capability alongside pronounced affordability and access disparities. Japan and South Korea have advanced healthcare infrastructure and growing attention to rare-disease pathways. Russia’s access environment is shaped by centralized policy, regional variation, and specialist availability. Across all countries, timely diagnosis, sustainable financing, treatment-center capacity, and long-term outcome monitoring remain central implementation issues.

Actionable Priorities for Leaders in SMA Injection Care

Industry leaders should support earlier identification through validated screening and referral pathways, while building evidence that reflects infants, children, adolescents, adults, and varied disease presentations. They should work with payers and providers on transparent eligibility criteria, continuity plans, administration capacity, and patient-support services without creating avoidable administrative burden. Investment in registries and interoperable outcomes data can strengthen real-world safety and effectiveness assessment. Training programs should expand the multidisciplinary workforce, and access strategies should address rural communities, underserved groups, and health-system differences. AI initiatives should proceed through governed pilots with clinical validation, cybersecurity controls, bias monitoring, and clear accountability.

Research Methodology for the Executive Summary

This executive summary uses the supplied market scope- injections for SMA-as a therapeutic and care-delivery category. The analysis is structured around established clinical and health-system dimensions: diagnosis, treatment administration, monitoring, reimbursement, specialist capacity, geographic access, research infrastructure, and responsible technology adoption. Regional, group, and country discussions are comparative and qualitative. No market estimates, market shares, forecasts, company-specific claims, or unsupported numerical assertions are included. Interpretation should be complemented by current regulatory decisions, clinical guidelines, peer-reviewed evidence, payer policies, and local health-system data.

Conclusion: Building More Equitable SMA Injection Pathways

The central opportunity in injections for SMA is to connect therapeutic innovation with earlier diagnosis, coordinated specialist care, reliable administration, and durable follow-up. Progress will depend not only on clinical evidence but also on financing, workforce development, screening access, data quality, and practical support for families. Regional and country conditions differ substantially, so implementation should be locally adapted while preserving consistent standards for safety, consent, monitoring, and outcomes. Responsible use of AI can reinforce these priorities when deployed transparently and under clinical governance.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Injections for SMA Market, by Mechanism Of Action
7.1. Introduction
7.2. Antisense Oligonucleotide Therapy
7.3. Gene Therapy
8. Injections for SMA Market, by Route Of Administration
8.1. Introduction
8.2. Intrathecal Injection
8.3. Intravenous Injection
9. Injections for SMA Market, by Indication
9.1. Introduction
9.2. Type I
9.3. Type II
9.4. Type III
9.5. Type IV
10. Injections for SMA Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Ambulatory Clinics
10.2.2. Specialty Clinics
10.3. Homecare Settings
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Injections for SMA Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Injections for SMA Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Injections for SMA Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Astellas Pharma Inc.
15.2. Audentes Therapeutics, Inc.
15.3. Audentes Therapeutics, Inc.
15.4. Biogen Inc.
15.5. Biohaven Pharmaceutical Holding Company Ltd.
15.6. BridgeBio Pharma, Inc.
15.7. Catalyst Pharmaceuticals, Inc.
15.8. Cytokinetics, Inc.
15.9. F. Hoffmann-La Roche Ltd.
15.10. Genentech, Inc.
15.11. Ionis Pharmaceuticals, Inc.
15.12. NMD Pharma A/S
15.13. Novartis AG
15.14. Novartis Gene Therapies, Inc.
15.15. Pfizer Inc.
15.16. PTC Therapeutics, Inc.
15.17. Regenxbio Inc.
15.18. Sarepta Therapeutics, Inc.
15.19. Scholar Rock, Inc.
15.20. Shionogi & Co., Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Injections for SMA Market, Years Considered for the Study
FIGURE 2. Global Injections for SMA Market, Research Design
FIGURE 3. Global Injections for SMA Market, Research Framework
FIGURE 4. Global Injections for SMA Market, Data Triangulation
FIGURE 5. Global Injections for SMA Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Injections for SMA Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 7. Global Injections for SMA Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Injections for SMA Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Injections for SMA Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Injections for SMA Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Injections for SMA Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Injections for SMA Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Injections for SMA Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Injections for SMA Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Injections for SMA Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Injections for SMA Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Injections for SMA Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Injections for SMA Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Injections for SMA Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Injections for SMA Market Segmentation & Coverage
TABLE 2. Global Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 3. Global Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotide Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotide Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotide Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 11. Global Intrathecal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Intrathecal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Intrathecal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Intravenous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Intravenous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Intravenous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 18. Global Type I Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Type I Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Type I Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Type II Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Type II Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Type II Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Type III Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Type III Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Type III Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Type IV Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Type IV Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Type IV Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Ambulatory Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ambulatory Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 60. North America Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. North America Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 62. North America Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 63. North America Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 64. North America Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. North America Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 66. North America Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 67. Latin America Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Latin America Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 69. Latin America Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 70. Latin America Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 71. Latin America Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. Latin America Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 73. Latin America Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 74. Europe Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Europe Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 76. Europe Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. Europe Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Europe Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Europe Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 80. Europe Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 81. Middle East Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Middle East Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 83. Middle East Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. Middle East Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Middle East Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Middle East Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 87. Middle East Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 88. Africa Injections for SMA Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Africa Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 90. Africa Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 91. Africa Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 92. Africa Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Africa Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 94. Africa Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 95. Global Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. ASEAN Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 98. ASEAN Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. ASEAN Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 100. ASEAN Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. ASEAN Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 102. ASEAN Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 103. GCC Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. GCC Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 105. GCC Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. GCC Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 107. GCC Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. GCC Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 109. GCC Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 110. European Union Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. European Union Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 112. European Union Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 113. European Union Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. European Union Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. European Union Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 116. European Union Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 117. BRICS Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. BRICS Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 119. BRICS Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. BRICS Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. BRICS Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. BRICS Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 123. BRICS Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 124. G7 Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. G7 Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 126. G7 Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. G7 Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. G7 Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. G7 Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 130. G7 Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 131. NATO Injections for SMA Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. NATO Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 133. NATO Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. NATO Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. NATO Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. NATO Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 137. NATO Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 138. Global Injections for SMA Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. United States Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 140. United States Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 141. United States Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. United States Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. United States Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. United States Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 145. United States Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 146. Canada Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 147. Canada Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 148. Canada Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. Canada Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 150. Canada Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Canada Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 152. Canada Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 153. Mexico Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 154. Mexico Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 155. Mexico Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. Mexico Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. Mexico Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Mexico Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 159. Mexico Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 160. Brazil Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 161. Brazil Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 162. Brazil Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. Brazil Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 164. Brazil Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Brazil Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 166. Brazil Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 167. United Kingdom Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 168. United Kingdom Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 169. United Kingdom Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. United Kingdom Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. United Kingdom Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. United Kingdom Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 173. United Kingdom Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 174. Germany Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 175. Germany Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 176. Germany Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. Germany Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. Germany Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Germany Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 180. Germany Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 181. France Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 182. France Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 183. France Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. France Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. France Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. France Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 187. France Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 188. Russia Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 189. Russia Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 190. Russia Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. Russia Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. Russia Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Russia Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 194. Russia Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 195. Italy Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 196. Italy Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 197. Italy Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. Italy Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 199. Italy Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Italy Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 201. Italy Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 202. Spain Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 203. Spain Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 204. Spain Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 205. Spain Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Spain Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. Spain Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 208. Spain Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 209. China Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 210. China Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 211. China Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. China Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. China Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. China Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 215. China Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 216. India Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 217. India Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 218. India Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. India Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. India Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. India Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 222. India Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 223. Japan Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 224. Japan Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 225. Japan Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. Japan Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. Japan Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. Japan Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 229. Japan Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 230. Australia Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 231. Australia Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 232. Australia Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. Australia Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. Australia Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Australia Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 236. Australia Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 237. South Korea Injections for SMA Market Size, 2017-2032 (USD Million)
TABLE 238. South Korea Injections for SMA Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 239. South Korea Injections for SMA Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. South Korea Injections for SMA Market Size, by Indication, 2017-2032 (USD Million)
TABLE 241. South Korea Injections for SMA Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. South Korea Injections for SMA Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 243. South Korea Injections for SMA Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 244. Global Injections for SMA Market Share, by Key Player, 2025
TABLE 245. Global Injections for SMA Market, Key Experts

Companies Mentioned

  • Astellas Pharma Inc.
  • Audentes Therapeutics, Inc.
  • Audentes Therapeutics, Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • BridgeBio Pharma, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Ionis Pharmaceuticals, Inc.
  • NMD Pharma A/S
  • Novartis AG
  • Novartis Gene Therapies, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Regenxbio Inc.
  • Sarepta Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Shionogi & Co., Ltd.

Related Topics

Related Reports

Icatibant Acetate Injection Market - Global Forecast 2026-2032 - Product Image

Icatibant Acetate Injection Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Pegcetacoplan Injection Market - Global Forecast 2026-2032 - Product Image

Pegcetacoplan Injection Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Joint Pain Injections - Global Strategic Business Report - Product Image

Joint Pain Injections - Global Strategic Business Report

  • Report
  • 378 Pages
  • Global
From
Lip injections - Global Strategic Business Report - Product Image

Lip injections - Global Strategic Business Report

  • Report
  • 474 Pages
  • Global
From
Paclitaxel Injection - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Paclitaxel Injection - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.